Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Newton Biocapital is a life sciences investment organization founded to leverage innovation in Europe and Japan. Established with a mission to develop solutions for chronic health conditions, the firm aims to create value for patients, society, local ecosystems, and investors. Newton Biocapital operates from its offices in Brussels, Belgium, and Tokyo, Japan, facilitating cross-border collaboration in the life sciences sector.
The organization currently manages a portfolio of 8 companies, focusing on early-stage investments in the life sciences. Newton Biocapital emphasizes a hands-on investment approach, actively participating in the strategic decisions and clinical programs of its portfolio companies. This engagement is designed to enhance the potential for successful outcomes and optimal exit strategies.
Notable milestones include the establishment of strong connections between the life sciences ecosystems of Europe and Japan, which allows for enhanced access to global pharmaceutical networks. This strategic positioning enables Newton Biocapital to support its portfolio companies effectively, ensuring they are well-equipped to tackle the challenges of chronic health conditions.
Newton Biocapital invests in early-stage companies within the life sciences sector, specifically targeting chronic health conditions such as oncology, autoimmune diseases, neurological diseases, metabolic diseases, and genetic diseases. The firm operates primarily in Europe and Asia, focusing on pre-seed, seed, and Series A stages. Investment checks typically align with the early-stage nature of the companies they support, although specific check sizes are not disclosed.
The organization employs a hands-on investment approach, actively participating as board members and providing strategic support to portfolio companies. This involvement includes guidance on clinical programs and strategic decisions, which is crucial for navigating the complexities of the life sciences industry. Newton Biocapital emphasizes collaboration between the life sciences ecosystems of Europe and Japan, facilitating access to global pharmaceutical networks and optimal exit strategies for its portfolio companies.
Newton Biocapital's portfolio consists of 8 notable companies, each focused on addressing chronic health conditions:
Alain Parthoens: Chief Executive Officer with extensive experience in life sciences investment and management.
Sadashi Suzuki: Japan Representative, facilitating connections between European and Japanese life sciences ecosystems.
Guy Heynen: Chief Medical and Regulatory Officer, bringing expertise in clinical development and regulatory affairs.
Michihiko Wada: Chief Regulatory and Development Officer, focusing on regulatory strategy and product development.
Danny Gonnissen: Chief Operating Officer, overseeing operational aspects of the firm.
Tomoko Asaoka: Scientific Director, providing scientific insights and guidance to portfolio companies.
Pierre Detrixhe: Venture Director, responsible for sourcing and evaluating investment opportunities.
Dario Padovani: Chief Financial Officer, managing financial operations and strategy.
Toko Senna: Assistant to the CEO and Office Manager in the Brussels office, supporting daily operations.
Ajit Shetty: Chairman of the Board of NBC I and NBC II, with a background in pharmaceutical leadership.
Dirk Boogmans: Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II, overseeing financial governance.
Jean Combalbert: Independent Director, providing independent oversight and guidance.
Jean-Claude Deschamps: Chairman Emeritus and Advisor to the Board of NBC I and NBC II, with a wealth of experience in the industry.
Goro Takeda: Founder of Newton Biocapital, instrumental in establishing the firm's vision and strategy.
To pitch to Newton Biocapital, founders should submit their proposals through the submission page on their website. It is important to include a comprehensive deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. While specific response time expectations are not provided, founders should anticipate a thorough review process given the firm's hands-on approach to investment.
As of March 2026, Newton Biocapital continues to actively engage with its portfolio companies, promoting its investment thesis focused on innovative solutions for chronic health conditions. The firm has been involved in supporting its portfolio companies through strategic guidance and operational support.
Recent updates highlight the firm's commitment to enhancing collaboration between the life sciences ecosystems of Europe and Japan, facilitating access to global pharmaceutical networks. This strategic focus positions Newton Biocapital as a key player in the life sciences investment landscape.
What are Newton Biocapital's investment criteria?
Newton Biocapital focuses on early-stage life sciences companies that address chronic health conditions. They specifically look for innovations in oncology, autoimmune diseases, neurological diseases, metabolic diseases, and genetic diseases.
How can I apply or pitch to Newton Biocapital?
Founders can submit business proposals through the submission page on Newton Biocapital's website. It is advisable to include detailed information about the business model, market potential, and team background in the pitch.
What makes Newton Biocapital different from other investors?
Newton Biocapital emphasizes a hands-on investment approach, actively participating in the strategic decisions and clinical programs of its portfolio companies. Their unique focus on bridging the life sciences ecosystems of Europe and Japan enhances their portfolio companies' access to global pharmaceutical networks.
What is the geographic scope of Newton Biocapital's investments?
The firm primarily invests in Europe and Asia, leveraging the strengths of both regions in the life sciences sector.
What is the typical fund size or check size for investments?
While specific fund sizes and check sizes are not disclosed, Newton Biocapital focuses on pre-seed, seed, and Series A investments, which typically involve smaller investment amounts compared to later-stage funding.
What kind of post-investment involvement can portfolio companies expect?
Newton Biocapital takes an active role in supporting its portfolio companies, often serving as board members and providing strategic guidance on clinical programs and business development. This involvement is designed to enhance the likelihood of successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.